Author

M. Andrake

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. J. Klein-Szanto· 1 shared A. Musa de Aquino· 1 shared B. Faezov· 1 shared C. Ogier· 1 shared D. Barbosa Vendramini-Costa· 1 shared D. I. Zhigarev· 1 shared E. Cukierman· 1 shared E. Malloy· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Klein-Szanto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer

D. Barbosa Vendramini-Costa, R. Francescone, J. Franco-Barraza, T. Luong, M. Graves, A. Musa de Aquino, N. G. Steele, J. C. Gardiner, S. A. Alcantara dos Santos, C. Ogier, E. Malloy, L. Borghaei, E. Martinez, D. I. Zhigarev, Y. Tan, , E. Cukierman

This paper identifies NGL-1 as a stromal immunomodulator in pancreatic cancer that promotes tumor growth by modulating the tumor microenvironment through TGF-β and transcription factor pathways.

bioRxiv · May 15, 2024 · PreprintCancer Biology

Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors.

S. S. Shah, E. V. Demidova, S. Ringenbach, B. Faezov, M. Andrake, P. Mur, J. Viana-Errasti, J. Xiu, J. Swensen, L. Valle, R. Dunbrack, M. J. Hall, S. Arora

The paper identifies co-occurring POLE mutations in both exonuclease and non-exonuclease domains as a novel driver of ultra-high tumor mutation burden in certain cancers.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology